Monash University and Brigham and Women’s Hospital (BWH) today announce the renewal of their landmark research partnership at a ceremony in Boston, Massachusetts. Australia’s largest university and one of Boston’s largest hospitals are advancing innovation in sleep and circadian medicine through a world-leading research initiative that will include investigating the […]
Research/Studies
The Syn-Sleep Study: Detection of Cutaneous Phosphorylated Alpha-Synuclein in REM Sleep Behavior Disorder
On Wednesday morning, CND Life Sciences presented exciting new data at SLEEP 2026 from the NIH-sponsored Syn-Sleep Study, indicating that its Syn-One Test detected phosphorylated alpha-synuclein (P-SYN) in 75% of patients with idiopathic REM sleep behavior disorder (RBD). SleepWorld had a chance to sit down with CND Chief Medical Officer and […]
Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker
Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of […]
Wesper to Unveil First Multi-Tier Sleep Diagnostic Ecosystem for Personalized Sleep Care at SLEEP 2026
Wesper unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right […]
New Survey Results Explore the Complexity of Marijuana Use and Sleep
New survey results from the American Academy of Sleep Medicine explore the complex relationship between marijuana use and sleep. One-third (33%) of adults reported that their sleep is slightly or significantly better when they use marijuana. In contrast, 19% of adults reported either no impact (11%) or that their sleep is […]
For Older Adults with Mild Cognitive Impairment, Exercise Can Be Crucial to Sleep Quality
Staying active is known to improve sleep, but the research findings are mixed regarding the best workout. Some studies say light walking or stretching is best, others prefer moderate-intensity workouts like jogging — and some even find that vigorous exercise such as swimming makes sleep worse. Resolving this discrepancy is […]
Nexalin Study Shows Brain-Network Changes and Sleep Improvement in Chronic Insomnia
Nexalin Technology, Inc. announced the online publication of a peer-reviewed study in Psychotherapy and Psychosomatics reporting significant clinical improvement and measurable brain-network modulation in patients with chronic insomnia treated with the Company’s high-power 15 mA, 77.5 Hz stimulation approach. The paper was published online on April 20, 2026. The study, titled: “Modulating […]
One in Three Americans Lose Sleep Over Healthcare Costs, New Survey Finds
A new national survey from Imagine360, a leading alternative health plan for self-funded employers, reveals a rising healthcare affordability crisis with 1 in 3 insured Americans saying they’re losing sleep over the cost of care. As employer-sponsored healthcare costs climb to record highs, nearly half (44%) of survey respondents are […]
Alkermes Announces Phase 3 Brilliance Studies Evaluating Alixorexton for Narcolepsy Type 1 and Type 2
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Eisai to Begin Enrolling Phase 2 Study in Patients With Narcolepsy
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]













